Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine

Alberto Garaventa, Claudio Gambini, Giampiero Villavecchia, Andrea Di Cataldo, Luigi Bertolazzi, Maria Rosa Pizzitola, Bruno De Bernardi, Riccardo Haupt

Research output: Contribution to journalArticle

Abstract

BACKGROUND. 131I-metaiodobenzylguanidine (131I-MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with moderate side effects such as hematologic and thyroid toxicity. However, with longer follow-up, other complications might occur. We describe our experience with second cancers occurring in children treated with 131I-MIBG and chemotherapy. METHODS. The clinical records of 119 consecutive NB cases treated with 131I-MIBG at a single institution between 1984 and 2001 were reviewed for the occurrence of a second malignant neoplasm (SMN). RESULTS. Overall, five cases of SMN occurred in the study patients. In particular, two cases of myeloid leukemia, one of angiomatous fibrous histiocytoma, one of malignant schwannoma, and one case of rhabdomyosarcoma were detected. The schwannoma and the rhabdomyosarcoma developed within the residual neuroblastic mass after first-line therapy. CONCLUSIONS. Should 131I-MIBG treatment become more broadly employed in the therapeutic strategy for neuroblastoma, the risk of second cancer will have to be taken into consideration. The organization of an international registry of subjects treated with 131I-MIBG might better define the frequency and features of second malignancies following this radiometabolic approach.

Original languageEnglish
Pages (from-to)1332-1338
Number of pages7
JournalCancer
Volume97
Issue number5
DOIs
Publication statusPublished - Mar 1 2003

Fingerprint

Second Primary Neoplasms
Neuroblastoma
Rhabdomyosarcoma
Neurilemmoma
Radiotherapy
Benign Fibrous Histiocytoma
Therapeutics
Myeloid Leukemia
Neural Crest
Pheochromocytoma
Registries
Thyroid Gland
Drug Therapy
Neoplasms

Keywords

  • I-metaiodobenzylguanidine
  • Neuroblastoma
  • Second cancer
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. / Garaventa, Alberto; Gambini, Claudio; Villavecchia, Giampiero; Di Cataldo, Andrea; Bertolazzi, Luigi; Pizzitola, Maria Rosa; De Bernardi, Bruno; Haupt, Riccardo.

In: Cancer, Vol. 97, No. 5, 01.03.2003, p. 1332-1338.

Research output: Contribution to journalArticle

Garaventa, A, Gambini, C, Villavecchia, G, Di Cataldo, A, Bertolazzi, L, Pizzitola, MR, De Bernardi, B & Haupt, R 2003, 'Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine', Cancer, vol. 97, no. 5, pp. 1332-1338. https://doi.org/10.1002/cncr.11167
Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer. 2003 Mar 1;97(5):1332-1338. https://doi.org/10.1002/cncr.11167
Garaventa, Alberto ; Gambini, Claudio ; Villavecchia, Giampiero ; Di Cataldo, Andrea ; Bertolazzi, Luigi ; Pizzitola, Maria Rosa ; De Bernardi, Bruno ; Haupt, Riccardo. / Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. In: Cancer. 2003 ; Vol. 97, No. 5. pp. 1332-1338.
@article{fb48a0d807a14648b8ec7412027f66d6,
title = "Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine",
abstract = "BACKGROUND. 131I-metaiodobenzylguanidine (131I-MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with moderate side effects such as hematologic and thyroid toxicity. However, with longer follow-up, other complications might occur. We describe our experience with second cancers occurring in children treated with 131I-MIBG and chemotherapy. METHODS. The clinical records of 119 consecutive NB cases treated with 131I-MIBG at a single institution between 1984 and 2001 were reviewed for the occurrence of a second malignant neoplasm (SMN). RESULTS. Overall, five cases of SMN occurred in the study patients. In particular, two cases of myeloid leukemia, one of angiomatous fibrous histiocytoma, one of malignant schwannoma, and one case of rhabdomyosarcoma were detected. The schwannoma and the rhabdomyosarcoma developed within the residual neuroblastic mass after first-line therapy. CONCLUSIONS. Should 131I-MIBG treatment become more broadly employed in the therapeutic strategy for neuroblastoma, the risk of second cancer will have to be taken into consideration. The organization of an international registry of subjects treated with 131I-MIBG might better define the frequency and features of second malignancies following this radiometabolic approach.",
keywords = "I-metaiodobenzylguanidine, Neuroblastoma, Second cancer, Toxicity",
author = "Alberto Garaventa and Claudio Gambini and Giampiero Villavecchia and {Di Cataldo}, Andrea and Luigi Bertolazzi and Pizzitola, {Maria Rosa} and {De Bernardi}, Bruno and Riccardo Haupt",
year = "2003",
month = "3",
day = "1",
doi = "10.1002/cncr.11167",
language = "English",
volume = "97",
pages = "1332--1338",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine

AU - Garaventa, Alberto

AU - Gambini, Claudio

AU - Villavecchia, Giampiero

AU - Di Cataldo, Andrea

AU - Bertolazzi, Luigi

AU - Pizzitola, Maria Rosa

AU - De Bernardi, Bruno

AU - Haupt, Riccardo

PY - 2003/3/1

Y1 - 2003/3/1

N2 - BACKGROUND. 131I-metaiodobenzylguanidine (131I-MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with moderate side effects such as hematologic and thyroid toxicity. However, with longer follow-up, other complications might occur. We describe our experience with second cancers occurring in children treated with 131I-MIBG and chemotherapy. METHODS. The clinical records of 119 consecutive NB cases treated with 131I-MIBG at a single institution between 1984 and 2001 were reviewed for the occurrence of a second malignant neoplasm (SMN). RESULTS. Overall, five cases of SMN occurred in the study patients. In particular, two cases of myeloid leukemia, one of angiomatous fibrous histiocytoma, one of malignant schwannoma, and one case of rhabdomyosarcoma were detected. The schwannoma and the rhabdomyosarcoma developed within the residual neuroblastic mass after first-line therapy. CONCLUSIONS. Should 131I-MIBG treatment become more broadly employed in the therapeutic strategy for neuroblastoma, the risk of second cancer will have to be taken into consideration. The organization of an international registry of subjects treated with 131I-MIBG might better define the frequency and features of second malignancies following this radiometabolic approach.

AB - BACKGROUND. 131I-metaiodobenzylguanidine (131I-MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with moderate side effects such as hematologic and thyroid toxicity. However, with longer follow-up, other complications might occur. We describe our experience with second cancers occurring in children treated with 131I-MIBG and chemotherapy. METHODS. The clinical records of 119 consecutive NB cases treated with 131I-MIBG at a single institution between 1984 and 2001 were reviewed for the occurrence of a second malignant neoplasm (SMN). RESULTS. Overall, five cases of SMN occurred in the study patients. In particular, two cases of myeloid leukemia, one of angiomatous fibrous histiocytoma, one of malignant schwannoma, and one case of rhabdomyosarcoma were detected. The schwannoma and the rhabdomyosarcoma developed within the residual neuroblastic mass after first-line therapy. CONCLUSIONS. Should 131I-MIBG treatment become more broadly employed in the therapeutic strategy for neuroblastoma, the risk of second cancer will have to be taken into consideration. The organization of an international registry of subjects treated with 131I-MIBG might better define the frequency and features of second malignancies following this radiometabolic approach.

KW - I-metaiodobenzylguanidine

KW - Neuroblastoma

KW - Second cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0345074094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345074094&partnerID=8YFLogxK

U2 - 10.1002/cncr.11167

DO - 10.1002/cncr.11167

M3 - Article

C2 - 12599242

AN - SCOPUS:0345074094

VL - 97

SP - 1332

EP - 1338

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -